Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
<p><strong>Objectives</strong> The Heart Protection Study (HPS) provides an opportunity to assess directly the effects of cholesterol-lowering therapy on major vascular events (defined as myocardial infarction, coronary death, stroke, or revascularization) in patients with peripher...
Prif Awdur: | Heart Protection Study Collaborative Group |
---|---|
Awduron Eraill: | The Society for Vascular Surgery |
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Elsevier
2007
|
Pynciau: |
Eitemau Tebyg
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
gan: Heart Protection Study Collaborative Group
Cyhoeddwyd: (2002) -
N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
gan: Emberson, JR, et al.
Cyhoeddwyd: (2007) -
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
gan: Collins, R, et al.
Cyhoeddwyd: (2004) -
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
gan: Mihaylova, B, et al.
Cyhoeddwyd: (2005) -
N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
gan: Emberson, J, et al.
Cyhoeddwyd: (2005)